ARV Treatment Increase IL-17 Serum Level in HIV Patients

The decreasing of Th-17 number or function affecting IL-17 production cause HIV virus replicate easier. With the ARV that suppress HIV virus replication, it is expected that IL-17 production can be repaired and TH-17 function can be recovered. Research conducted to discover the average of IL-17 serum on HIV patients before and after 3 months of ARV therapy. Pre and post test survey was conducted on newly diagnosed HIV patients in Saiful Anwar General Hospital Malang. Diagnosis of HIV infection was based on WHO criteria and IL-17 serum measured with ELISA method, meanwhile CD4-Lymphocyte T counting using flowcytometry. Statistical analysis of numeric comparison using paired T test and correlation analysis using Spearman test. IL-17 serum level of HIV patient before and 3 months after ARV therapy was 44,17±12,56 pg/mL and 52,91±9,90 pg/mL (p=0,005). CD4-Lymphocyte T counting before and 3 months after ARV therapy was 69,41±95,06 cells/mL and 180,72±73,15 cells/mL (p=0,000). It is found that IL-17 serum level has no correlation with absolute CD4Lymphocyte T counting (p=0,914, r=-0,024). It can be concluded that IL-17 serum and CD4 of HIV patients after 3 months of ARV was higher compared to before therapy, but IL-17 serum level has no correlation with CD4-Lymphocyte T counting.